Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine.

Citation metadata

Date: Jan. 5, 2021
Publisher: BioMed Central Ltd.
Document Type: Article
Length: 7,615 words
Lexile Measure: 1460L

Document controls

Main content

Abstract :

Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal malignancy, with an average 5-year survival rate of 9% (Siegel RL, Miller KD, Jemal A. Ca Cancer J Clin. 2019;69(1):7-34). The steady increase in mortality rate indicates limited efficacy of the conventional regimen. The heterogeneity of PDAC calls for personalized treatment in clinical practice, which requires the construction of a preclinical system for generating patient-derived models. Currently, the lack of high-quality preclinical models results in ineffective translation of novel targeted therapeutics. This review summarizes applications of commonly used models, discusses major difficulties in PDAC model construction and provides recommendations for integrating workflows for precision medicine. Keywords: Pancreatic cancer, Preclinical model, Precision medicine

Source Citation

Source Citation   

Gale Document Number: GALE|A650588105